|1.||Sun, Yang: 2 articles (04/2014 - 10/2012)|
|2.||Xu, Qiang: 2 articles (04/2014 - 10/2012)|
|3.||Shen, Yan: 2 articles (04/2014 - 10/2012)|
|4.||Yang, J: 1 article (01/2015)|
|5.||Fan, Y: 1 article (01/2015)|
|6.||Patel, R H: 1 article (01/2015)|
|7.||Kim, E S: 1 article (01/2015)|
|8.||Liu, Xiao-Dan: 1 article (01/2015)|
|9.||Ding, Xu: 1 article (01/2015)|
|10.||Xing, Guo-Gang: 1 article (01/2015)|
|1.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
01/01/2015 - "In an intrarenal mouse model of NB, NSC-87877 treatment results in decreased tumor growth and increased p53 and p38 activity. "
01/01/2015 - "Together, these results suggest that DUSP26 inhibition with NSC-87877 is an effective strategy to induce NB cell cytotoxicity in vitro and in vivo through activation of the p53 and p38 mitogen-activated protein kinase (MAPK) tumor-suppressor pathways. "
08/01/2012 - "To translate these findings into a therapeutic application we tested the NP delivery of NSC-87877, a dual inhibitor of Shp1 and Shp2, key phosphatases that downregulate T-cell receptor activation in the synapse, in the context of adoptive T cell therapy of cancer. "
05/01/2012 - "SHP2 siRNA led to similar effects as the NSC-87877 and SIRPα1 antibody treatments, except it prevented the allodynia-associated spinal SHP2 expression. "
05/01/2012 - "Intrathecal administration of NSC-87877 (an SHP2 antagonist; 1, 10, or 100μM/rat) and SIRPα1-neutralizing antibodies (1, 10, or 30μg/rat) suppressed spinal nerve ligation-induced allodynia, spinal SHP2 and NR2B phosphorylation, and SHP2/phosphorylated SHP2-PSD-95 and PSD-95-NR2B/phosphorylated NR2B coprecipitation. "
01/01/2015 - "Blockade of SHP2 phosphorylation in the spinal dorsal horn using a potent SHP2 protein tyrosine phosphatase inhibitor NSC-87877, or knockdown of spinal SHP2 by intrathecal delivery of SHP2 siRNA, not only prevents BDNF-mediated GluN2B-NMDA receptors activation as well as spinal LTP induction and pain allodynia elicitation in intact rats, but also reduces the SNL-evoked GluN2B-NMDA receptors up-regulation and spinal LTP occlusion, and ultimately alleviates pain allodynia in neuropathic rats. "
|5.||Relapsing-Remitting Multiple Sclerosis
|1.||Protein Tyrosine Phosphatases
|2.||Small Interfering RNA (siRNA)
|3.||Brain-Derived Neurotrophic Factor (BDNF)
|4.||T-Cell Antigen Receptors (T-Cell Receptor)
|5.||Protein Kinases (Protein Kinase)
|6.||Phosphoric Monoester Hydrolases (Phosphatases)